Menopausal hormone therapy (HT) aims to improve a woman's quality of life by treating bothersome menopausal symptoms associated with low estrogen levels. Although HT is prescribed to millions of women worldwide, its breast-related adverse effects have always been a concern. Some of the common adverse effects of HT are breast fullness, increased breast density, and increased breast cancer (BC) risk. Health care professionals need to be aware of the influence of HT on breast tissue to provide appropriate counseling as part of informed decision making. Our review summarizes the influence of HT on breast symptoms, breast density, mammograms, and BC risk.
Get full access to this article
View all access options for this article.
References
1.
GroenJW, GrosfeldS, WilschutJA, BramerWM, ErnstMF, MullenderMM. Cyclic and non-cyclic breast-pain: A systematic review on pain reduction, side effects, and quality of life for various treatments. Eur J Obstet Gynecol Reprod Biol, 2017; 219:74–93.
2.
ZhaoS, ZhangX, ZhongH, et al.Background parenchymal enhancement on contrast-enhanced spectral mammography: Influence of age, breast density, menstruation status, and menstrual cycle timing. Sci Rep, 2020; 10:8608.
3.
HjerkindKV, Ellingjord-DaleM, JohanssonALV, et al.Volumetric mammographic density, age-related decline, and breast cancer risk factors in a national breast cancer screening program. Cancer Epidemiol Biomarkers Prev, 2018; 27:1065–1074.
4.
Nams Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause, 2017; 24:728–753.
5.
MillerVM, NaftolinF, AsthanaS, et al.The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned?. Menopause, 2019; 26:1071–1084.
6.
CrandallCJ, KarlamanglaA, HuangMH, UrsinG, GuanM, GreendaleGA. Association of new-onset breast discomfort with an increase in mammographic density during hormone therapy. Arch Intern Med, 2006; 166:1578–1584.
7.
MainieroMB, LourencoA, MahoneyMC, et al.ACR appropriateness criteria breast cancer screening. J Am Coll Radiol, 2013; 10:11–14.
8.
McCormackVA, dos Santos SilvaI. Breast density and parenchymal patterns as markers of breast cancer risk: A meta-analysis. Cancer Epidemiol Biomarkers Prev, 2006; 15:1159–1169.
9.
SartorH, BorgquistS, HartmanL, ZackrissonS. Do pathological parameters differ with regard to breast density and mode of detection in breast cancer? The Malmo Diet and Cancer Study. Breast, 2015; 24:12–17.
10.
KerlikowskeK, ZhuW, HubbardRA, et al.Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy. JAMA Intern Med, 2013; 173:807–816.
11.
RutterCM, MandelsonMT, LayaMB, SegerDJ, TaplinS. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA, 2001; 285:171–176.
12.
GreendaleGA, ReboussinBA, SloneS, WasilauskasC, PikeMC, UrsinG. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst, 2003; 95:30–37.
13.
TopalNB, AyhanS, TopalU, BilginT. Effects of hormone replacement therapy regimens on mammographic breast density: The role of progestins. J Obstet Gynaecol Res, 2006; 32:305–308.
14.
McTiernanA, MartinCF, PeckJD, et al.Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst, 2005; 97:1366–1376.
15.
LundstromE, WilczekB, von PalffyZ, SoderqvistG, von SchoultzB. Mammographic breast density during hormone replacement therapy: Effects of continuous combination, unopposed transdermal and low-potency estrogen regimens. Climacteric, 2001; 4:42–48.
16.
HoflingM, LundstromE, AzavedoE, SvaneG, HirschbergAL, von SchoultzB. Testosterone addition during menopausal hormone therapy: Effects on mammographic breast density. Climacteric, 2007; 10:155–163.
17.
HarveyJ, ScheurerC, KawakamiFT, Quebe-FehlingE, de PalaciosPI, RagavanVV. Hormone replacement therapy and breast density changes. Climacteric, 2005; 8:185–192.
18.
AzamS, LangeT, HuynhS, et al.Hormone replacement therapy, mammographic density, and breast cancer risk: A cohort study. Cancer Causes Control, 2018; 29:495–505.
19.
YaghjyanL, TamimiRM, BertrandKA, et al.Interaction of mammographic breast density with menopausal status and postmenopausal hormone use in relation to the risk of aggressive breast cancer subtypes. Breast Cancer Res Treat, 2017; 165:421–431.
20.
LowrySJ, Aiello BowlesEJ, AndersonML, BuistDS. Predictors of breast density change after hormone therapy cessation: Results from a randomized trial. Cancer Epidemiol Biomarkers Prev, 2011; 20:2309–2312.
21.
KavanaghAM, CawsonJ, ByrnesGB, et al.Hormone replacement therapy, percent mammographic density, and sensitivity of mammography. Cancer Epidemiol Biomarkers Prev, 2005; 14:1060–1064.
22.
BuistDS, AndersonML, ReedSD, et al.Short-term hormone therapy suspension and mammography recall: A randomized trial. Ann Intern Med, 2009; 150:752–765.
23.
HarveyJA, BovbjergVE. Quantitative assessment of mammographic breast density: Relationship with breast cancer risk. Radiology, 2004; 230:29–41.
24.
ChlebowskiRT, HendrixSL, LangerRD, et al.Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative Randomized Trial. JAMA, 2003; 289:3243–3253.
25.
SpragueBL, Trentham-DietzA, GangnonRE, et al.Circulating sex hormones and mammographic breast density among postmenopausal women. Horm Cancer, 2011; 2:62–72.
26.
von SchoultzB. The effects of tibolone and oestrogen-based HT on breast cell proliferation and mammographic density. Maturitas, 2004; 49:S16–S21.
27.
ByrneC, UrsinG, MartinCF, et al.Mammographic density change with estrogen and progestin therapy and breast cancer risk. J Natl Cancer Inst, 2017; 109.
